ASHP therapeutic position statement on the institutional use of 0.9% sodium chloride injection to maintain patency of peripheral indwelling intermittent infusion devices.
D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects; D002406:Catheterization, Peripheral / Q000379:methods*; D002408:Catheters, Indwelling; D002986:Clinical Trials as Topic; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007262:Infusions, Intravenous / Q000295:instrumentation; D012957:Societies, Pharmaceutical; D012965:Sodium Chloride / Q000008:administration & dosage*; D014481:United States
D000925:Anticoagulants; D012965:Sodium Chloride; D006493:Heparin